News About: R&D
Eased responsibilities for challenging research failures
In order to promote R&D, the government will ease responsibilities for failures, but tighten restrictions on repeated wrongful uses of R&D expenses.
The Ministry of Trade, Industry and Energy(Minister Woon-Kyu Baek, ...
7 of 11 biosimilars approved in Korea were developed by Korean company
It was reported there were the total 11 biosimilar products approved in Korea, such as ‘Remsima 100mg,’ and 7 of them were developed by Korean pharmaceutical companies.
According to the Ministry of Food and Drug Safe...
Will the Pangyo era come with R&D center for small & medium pharmas?
Korea Pharmaceutical Ind. Coop. Chairman Yong-Jun Cho visited the Gyeonggi Provincial Government in the afternoon of the 4th and exchanged various opinions about small and medium pharmaceutical companies’ future direc...
How to evaluate and report safety for drug clinical trials?
A guideline for safety evaluation and report was prepared for pharmaceutical companies to use at drug clinical trials.
Pharmaceutical companies, clients for clinical trial, must have a person taking in charge of moni...
“352 Korean clinical trials were approved in 1st half of this year”
The Korea National Enterprise for Clinical Trials(Chairman Dong-Hyun Ji, KoNETC) revealed the pharmaceutical clinical trial registration status in the 1st half of 2017 at ClinicalTrials.gov, the world’s largest clinic...
Qurient acquires patent of Quinolinyloxyphenylsulfonamides related to cancer treatment
Qurient gave an official notice on the 12th that it acquired a patent of Quinolinyloxyphenylsulfonamides related to cancer treatment.
According to the company, the patent is about the core chemical structure of the a...
Subject of bioequivalence test will be extended to powder and granule
Bioequivalence tests, which have only been conducted on tablets, capsules and suppositories, will be extended to powder and granule products from November 2018.
The Ministry of Food and Drug Safety(MFDS) held the ‘Ci...
“It is not required to conduct animal studies for biosimilar development in some countries”
It was observed it was not required to conduct animal studies in the progress of developing biosimilars in some countries.
At the ‘Global Bio Conference’ at Intercontinental Coex Seoul on the 29th, Dr. Jian Wang(Heal...
Hanmi’s 3-sbustance combination drug containing Amosartan & rosuvastatin represented at EHS
2 case results of clinical trial for ‘Amosartan,’ a combination drug developed by Hanmi Pharm, were announced at the European Society of Hypertension(ESH).
Hanmi Pharm announced on the 20th that it presented a Phase ...
Hanmi Pharm presents study results of LAPSCOVERY at ADA
2 candidate substances of biologic applied with ‘LAPSCOVERY,’ Hanmi Pharm’s own platform technology, were revealed at the world’s largest diabetes association American Diabetes Association(ADA).
Hanmi Pharm(CEO Sae-C...
Which are outstanding tetravalent vaccines even for the young?
Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer
Who will be the next Pharmaceutical Safety Bureau Director?
Celltrion completes clinical trials for Remsima SC for European approval
Sales listed pharmas made in the first half of the year
March
January
February
March
April
May
June
July
August
September
October
November
December
2025
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
|---|---|---|---|---|---|---|
23 | 24 | 25 | 26 | 27 | 28 | 1 |
2 | 3 | 4 | 5 | 6 | 7 | 8 |
9 | 10 | 11 | 12 | 13 | 14 | 15 |
16 | 17 | 18 | 19 | 20 | 21 | 22 |
23 | 24 | 25 | 26 | 27 | 28 | 29 |
30 | 31 | 1 | 2 | 3 | 4 | 5 |
00:00
01:00
02:00
03:00
04:00
05:00
06:00
07:00
08:00
09:00
10:00
11:00
12:00
13:00
14:00
15:00
16:00
17:00
18:00
19:00
20:00
21:00
22:00
23:00
